1.Use of lower trapezius musculocutaneous pedicle flap in repairing of maxillofacial region penetrating defect.
Yong-jun DU ; Ju-feng CHEN ; Qing-sheng LI ; Zhong-nan ZUO ; Xiang-sheng FENG ; Rui SHEN
Chinese Journal of Plastic Surgery 2005;21(6):423-425
OBJECTIVETo investigate an safe and effective new technology (treatment) to repair maxillofacial region penetrating defect.
METHODSThe lower trapezius musculocutaneous flap is parallel just like as two leaves which is connected to each other, and was folded to provide the liner of oral cavity and external cover.
RESULTSTotally twelve folding lower trapezius musculocutaneous pedicle flap survived. Postoperative follow-up for 1 approximately 3 years, the patients restored the function as well as the shape of maxillofacial region.
CONCLUSIONSThe lower trapezius musculocutaneous pedicle flap is a suitable material for maxillofacial region reconstruction, further more, the successful rate is perfect.
Female ; Humans ; Male ; Mouth Neoplasms ; surgery ; Muscle, Skeletal ; transplantation ; Oral Surgical Procedures ; methods ; Reconstructive Surgical Procedures ; methods ; Skin Transplantation ; methods ; Surgical Flaps ; Treatment Outcome
2.Case-control study on manipulation combined with Chinese herbs for the treatment of lumbar disc herniation within chronic stage.
Yu ZHANG ; Guan-nan WU ; Xing LI ; Yong-dong ZHANG ; Zuo-xu LI ; Ming MA ; Zhong-min LEI ; Jun-jie LI
China Journal of Orthopaedics and Traumatology 2011;24(11):926-929
OBJECTIVETo observe and compare the therapeutic effects of two methods to lumbar disc herniation treated by manipulation combined with Chinese herbs and traction with Western medicine.
METHODSA multi-center with a central district unit was used to study the patients with lumbar disc herniation from November 28th, 2008 to May 7th, 2010. All the patients were divided into treatment group and control group. The treatment group had 100 cases, including 45 males and 55 females, averaged (43.43 +/- 9.18) years. The treatment group was treated by manipulation combined with Chinese herbs; Control group had 100 cases (5 cases were fall off), including 38 males and 57 females, averaged (42.29 +/- 9.78) years. The control group was treated by traction with Western medicine. The course of treatment was 3 weeks. VAS, M-JOA, LMS (lower limb muscle strength) and classification efficacy was used to evaluate outcome and therapeutic effects before and after treatment.
RESULTSVAS and M-JOA were improved after the treatment both in treatment group and control group; there was no significant difference in LMS before and after treatment in both groups. VAS and M-JOA in treatment group was superior to those of control group after treatment. There was no significant difference in LMS. According to classification efficacy, 41 cases got excellent result, 34 good, 13 fair and 12 poor in treatment group; in control group, 35 cases obtained excellent results, 16 good, 19 fair and 25 poor. The effect of treatment group was better than that of control group.
CONCLUSIONBoth of two methods can improve the score of VAS, M-JOA, and treatment group is better than that of control group. While for the improvement of LMS, both of two methods have no obvious effects.
Adult ; Case-Control Studies ; Chronic Disease ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Intervertebral Disc Displacement ; therapy ; Lumbar Vertebrae ; Male ; Manipulation, Orthopedic ; Middle Aged ; Traction
3.Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin treatment.
Zuo-Yi JIAO ; Lü-Nan YAN ; Bo LI ; Yong ZENG ; Tian-Fu WEN ; Shi-Chun LU ; Ji-Chun ZHAO ; Wen-Tao WANG ; Ming-Qing XU ; Jia-Yin YANG ; Zhi-Hui LI ; Yu-Kui MA ; Zhong-Wei ZHANG ; Zhe-Yu CHEN
Chinese Journal of Hepatology 2007;15(11):804-808
OBJECTIVEThe aim of this study was designed to evaluate the outcomes of liver transplant recipients with chronic hepatitis B (CHB) receiving either lamivudine monotherapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin (HBIG) therapy.
METHODSA total of 111 liver transplant recipients with CHB were divided not randomly into two groups according to the availability of HBIG before liver transplantation (LT). Thirty-two patients received lamivudine monotherapy (100 mg/d) and 79 patients received lamivudine (100 mg/d) combined with individualized low-dose HBIG (intramuscular administration) to maintain the titer of antibody to hepatitis B virus (HBV) surface antigen (anti-HBs) not less than 100 U/L. The patients were followed-up for a median time of 32 months (1 to 88 months).
RESULTSIn the lamivudine monotherapy group, 5 patients hepatitis B relapsed (3/5 developed YMDD mutants of HBV), with 1-, 2-, and 3-year cumulative recurrence rates of 7.1%, 14.3% and 17.9% and survival rates of 87.5%, 84.4% and 74.6%. In the lamivudine and HBIG combination therapy group, 2 patients hepatitis B relapsed (2/2 developed YMDD mutants of HBV), with 1-, 2-, and 3-year cumulative recurrence rates of 0, 1.8% and 5.7% (P < 0.01) and survival rates of 83.5%, 80.9% and 77.6% (P > 0.05).
CONCLUSIONSCompared with lamivudine monotherapy, lamivudine combined with individualized low-dose HBIG can further reduce the recurrence risk of hepatitis B in liver transplant recipients. This combined therapy could be used as a rational strategy for prophylaxis of hepatitis B recurrence in such patients.
Adult ; Antiviral Agents ; therapeutic use ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hepatitis B ; pathology ; prevention & control ; Hepatitis B virus ; immunology ; Humans ; Immunoglobulins ; therapeutic use ; Lamivudine ; therapeutic use ; Liver Transplantation ; Male ; Middle Aged ; Secondary Prevention
4. A population-based survey of gastroesophageal reflux disease in a region with high prevalence of esophageal cancer in China
Kun WANG ; Li ZHANG ; Zhong-Hu HE ; Zuo-Jing LIU ; Lu ZHANG ; Nan HU ; Zhu JIN ; Yang KE ; Li-Ping DUAN
Chinese Medical Journal 2019;132(13):1516-1523
Background:
The exact relationship between gastroesophageal reflux disease (GERD) and esophageal squamous cell cancer (ESCC) is far from clarification. The aim of this study was to investigate the epidemiology of GERD in a region with high prevalence of ESCC in China.
Methods:
A population-based, cross-sectional study was conducted in a high ESCC prevalent area, Anyang, Henan, China. All subjects fulfilled questionnaires and underwent gastroendoscopy with routine esophageal biopsy. The subjects were divided into GERD subtypes (reflux esophagitis [RE] and non-erosive reflux disease [NERD]) and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to examine risk factors for RE and NERD.
Results:
A total of 2844 subjects were finally enrolled. The prevalence of GERD (RE + NERD) was 17.3%. Among them, 271 (9.53%) adults were diagnosed with RE. The prevalence of RE increased with age (7.09% in 45–50 years, 8.00% in 51–60 years, and 9.53% in 61–69 years,
5.Epidemiological and clinical features of functional dyspepsia in a region with a high incidence of esophageal cancer in China.
Nan HU ; Kun WANG ; Li ZHANG ; Zuo-Jing LIU ; Zhu JIN ; Rong-Li CUI ; He-Jun ZHANG ; Zhong-Hu HE ; Yang KE ; Li-Ping DUAN
Chinese Medical Journal 2021;134(12):1422-1430
BACKGROUND:
Functional dyspepsia (FD) has rarely been investigated in areas with a high prevalence of esophageal squamous cell carcinoma (ESCC). This study aims to reveal the epidemiological and clinical features of FD and organic dyspepsia (OD) in such a population.
METHODS:
A middle-aged and elderly population-based study was conducted in a region with a high incidence of ESCC. All participants completed the Gastroesophageal Reflux Disease Questionnaire and Functional Gastrointestinal Disease Rome III Diagnostic Questionnaire, and they underwent gastroscopy. After exclusion of gastroesophageal reflux disease, uninvestigated dyspepsia (UID) was divided into OD and FD for further analyses.
RESULTS:
A total of 2916 participants were enrolled from July 2013 to March 2014 in China. We detected 166 UID cases with questionnaires, in which 17 patients with OD and 149 with FD were diagnosed via gastroscopy. OD cases presented as reflux esophagitis (RE), ESCC, and duodenal ulcer. Heartburn (52.94%) and reflux (29.41%) were common in OD, but no symptomatic differences were found between FD and OD. Male sex, low education level, and liquid food were the risk factors for OD, while frequent fresh vegetable consumption was a protective factor. FD included 56 (37.58%) cases of postprandial distress syndrome (PDS), 52 (34.89%) of epigastric pain syndrome (EPS), nine (6.04%) of PDS + EPS, and 32 (21.48%) of FD + functional esophageal disorders. The Helicobacter pylori infection rate in FD patients was not higher than that in the control group (34.23% vs. 42.26%, P = 0.240). Frequent spicy food consumption was associated with PDS (odds ratio [OR]: 2.088, 95% confidence interval [CI]: 1.028-4.243), while consumption of deep well water was protective for PDS (OR: 0.431, 95% CI: 0.251-0.741).
CONCLUSIONS:
The prevalence of FD was 5.11% in the studied population. Gastroscopy should be prescribed for dyspepsia patients in case that ESCC and RE would be missed in UID cases diagnosed solely by the Rome III questionnaire.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT01688908; https://clinicaltrials.gov/ct2/show/record/NCT01688908.
Aged
;
China/epidemiology*
;
Dyspepsia/epidemiology*
;
Esophageal Neoplasms/epidemiology*
;
Esophageal Squamous Cell Carcinoma
;
Helicobacter Infections
;
Helicobacter pylori
;
Humans
;
Incidence
;
Male
;
Middle Aged